A New Chlamydia Vaccine on the Horizon
A first-in-human, Phase I clinical trial was successfully completed for a chlamydia vaccine, which is...
Are M&As the Key to Securing Growth in the Orphan Drugs Sector?
The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these...
Pharma Technology Focus: Scottish pharma gets a health check
In this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced...
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in...
Find out about the foundation for the first drugs using microbiome bacteria in the latest issue of Pharma Technology Focus
In this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based...
Pharma Technology Focus – Issue 77
In this issue: China’s growing pharmaceutical market, antimicrobial resistance, the rise of tech giants in...
Pharma Technology Focus – Issue 76
In this issue: HPV vaccine programmes, dominantly inherited Alzheimer’s disease, a unique brain ‘fingerprint’ and...
Pharma Technology Focus – Special Issue
In this issue: Manufacturing personalised medicine, the economics of CAR-T treatments, AI in drug combination...
Pharma Technology Focus – Issue 74
In this issue: Boosting trust in big pharma, the highs and lows of the world’s...
GSK invests $300m in 23andMe under drug development deal
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research...